Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international n.v.   - paliperidono palmitatas - Šizofrenija - psicholeptikai - byannli (previously paliperidone janssen-cilag international) a 6 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly or 3 monthly paliperidone palmitate injectable products (see section 5.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

basf uab, spaudos g. 6-1, lt-05132, vilnius. - flokumafenas, cis,trans-1-(4-chlorofenil)-4,4-dimetil-3-(1,2,4-triazol-1-ilmetil)pentan-3-olas, 1,+ 1-(4-chlorofenil)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-olas - veikliosios medžiagos cas nr.: 90035-08-8, eb nr.: 421-960-0, veikliosios medžiagos pavadinimas: flokumafenas, cis,trans-1-(4-chlorofenil)-4,4-dimetil-3-(1,2,4-triazol-1-ilmetil)pentan-3-olas, 1,+ 1-(4-chlorofenil)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-olas, koncentracija: 0.0025% , veiklioji - rodenticidai

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - amino rūgšties metabolizmas, įgimtos klaidos - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland - prucalopride sukcinatas - vidurių užkietėjimas - kiti narkotikai užkietėjimui - resolor skiriamas simptominiam lėtinio vidurių užkietėjimo gydymui suaugusiems žmonėms, kuriems negalima pakankamai atsipalaiduoti.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

uab basf, sausio 13-osis 4a, lt-04343, vilnius. - flokumafenas, cis,trans-1-(4-chlorofenil)-4,4-dimetil-3-(1,2,4-triazol-1-ilmetil)pentan-3-olas, 1,+ 1-(4-chlorofenil)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-olas - veikliosios medžiagos cas nr.: 90035-08-8, eb nr.: 421-960-0, veikliosios medžiagos pavadinimas: flokumafenas, cis,trans-1-(4-chlorofenil)-4,4-dimetil-3-(1,2,4-triazol-1-ilmetil)pentan-3-olas, 1,+ 1-(4-chlorofenil)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-olas, koncentracija: 0.0025% , veiklioji - rodenticidai

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

intervet international b.v. - fluralaner, ožkos - antiparasitic products, insecticides and repellents, endectocides, milbemycins - katės - katėms, arba gresia, sumaišyti parazitinės invazijos pagal erkių ar blusų ir ausų erkių, virškinimo trakto nematodų ar heartworm. veterinarinis vaistas yra tik nurodyta, kada naudoti nuo erkių ar blusų ir vienas ar daugiau kitų tikslinių parazitų, yra nurodyta, tuo pačiu metu. gydymo erkių ir blusų invazijos katės suteikti neatidėliotiną ir nuolat blusų (ctenocephalides felis) ir erkių (ixodes ricinus) žuvo veikla 12 savaičių. blusos ir erkės turi pridėti prie kompiuterio ir pradėti šerti siekiant sąlyčio su veikliąja medžiaga. produktas gali būti naudojamas kaip blusų alerginio dermatito (fad) gydymo strategijos dalis.. gydymo antplūdžių su ausų erkutės (otodectes cynotis). gydymo infekcijų, žarnyno roundworm (4 stadijos lervos, nesubrendęs suaugusiųjų ir suaugusiems toxocara cat) ir hookworm (4 stadijos lervos, nesubrendęs suaugusiųjų ir suaugusiems ancylostoma tubaeforme). kai vartojamas kelis kartus per 12 savaičių intervalu, produktas nuolat neleidžia heartworm liga, kurią sukelia dirofilaria immitis.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international nv - darunaviras - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international nv - kanagliflozinas - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ir 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozinas - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - narkotikai, vartojami diabetu - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ir 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - hidrokortizonas - antinksčių nepakankamumas - kortikosteroidų sisteminis naudoti - suaugusiųjų antinksčių nepakankamumo gydymas.